查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510454

gRNA 市场 - 全球产业规模、份额、趋势、机会和预测，按类型、产品和服务（产品、客製化 gRNA 合成服务）、应用、最终用途、地区和竞争细分，2019-2029 年

gRNA Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product & Services (Product, Custom gRNA Synthesis Services), By Application, By End-Use, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球 gRNA 市场价值为 4.9823 亿美元，预计到 2029 年将以 18.54% 的复合年增长率成长。随着生物技术和分子生物学的进步不断加速，对精确、高效的基因组编辑工具的需求显着上升，推动了gRNA市场的扩张。 gRNA 是 CRISPR（成簇规则间隔短回文重复序列）技术的关键组成部分，可实现基因的标靶修饰。这项革命性技术可应用于各个领域，包括农业、医疗保健和研究。在农业中，在基于 CRISPR 的基因组编辑中使用 gRNA 有可能透过增强产量、抗病性和营养成分等性状来彻底改变作物改良。医疗保健产业也见证了 gRNA 技术用于治疗目的的激增，包括开发针对遗传性疾病和癌症的新型疗法。 gRNA 的多功能性使科学家和研究人员能够精确定位和修改特定基因，为个人化医疗开闢了可能性。 gRNA 市场的特点是持续不断的研究和开发活动，旨在完善和扩展 CRISPR 技术的能力。开发更有效率、更精确的基因组编辑工具的竞赛促进了生技公司、学术机构和研究组织之间的合作。因此，gRNA 市场预计在未来几年将持续成长。然而，与基因组编辑技术相关的伦理和监管挑战，包括对脱靶效应和意外后果的担忧，对市场的扩张构成了潜在的障碍。在技​​术进步和伦理考量之间取得平衡对于 gRNA 市场的持续成长至关重要。儘管面临挑战，gRNA 技术的潜在应用和变革性影响使其成为快速发展的基因工程领域的焦点。

市场概况
预测期 2025-2029
2023 年市场规模 4.9823亿美元
2029 年市场规模 137040万美元
2024-2029 年复合年增长率 18. 54%
成长最快的细分市场 製药与生物技术公司
最大的市场 北美洲

主要市场驱动因素

基因工程的进展

增加研发活动

对个人化医疗的需求不断增长

主要市场挑战

脱靶效应

配送方式

主要市场趋势

治疗应用

专注于 CRISPR-Cas 系统

细分市场洞察

产品与服务见解

最终用途见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：客户之声

第 4 章：执行摘要

第 5 章：全球 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（研究用途、GMP 级）
    • 按产品和服务（产品（gRNA 最终产品、gRNA 合成产品、gRNA 合成试剂盒、质粒、其他））、客製化 gRNA 合成服务）
    • 按应用（基因组工程、疾病模型研究、功能基因体学、表观遗传学等）
    • 按最终用途（製药和生物技术公司、学术研究机构、CMO 和 CRO）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按地区

第 6 章：亚太 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 gRNA 市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按产品和服务
    • 按申请
    • 按最终用途
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布（如有）
  • 併购（如有）

第 13 章：全球 gRNA 市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • System Biosciences, LLC
  • Jena Bioscience GmbH
  • Merck KGaA
  • Azenta Us, Inc.
  • Takara Bio, Inc.
  • Synbio Technologies
  • Revvity, Inc.
  • Synthego Corporation

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 23789

Global gRNA Market was valued at USD 498.23 million in 2023 and is anticipated to grow with a CAGR of 18.54% through 2029. The gRNA (guide RNA) market has emerged as a dynamic and promising sector within the field of genetic engineering and genome editing. As advancements in biotechnology and molecular biology continue to accelerate, the demand for precise and efficient genome editing tools has risen significantly, driving the expansion of the gRNA market. gRNA serves as a critical component in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, which enables targeted modification of genes. This revolutionary technology has applications across various sectors, including agriculture, healthcare, and research. In agriculture, the use of gRNA in CRISPR-based genome editing has the potential to revolutionize crop improvement by enhancing traits such as yield, resistance to diseases, and nutritional content. The healthcare industry is also witnessing a surge in the adoption of gRNA technology for therapeutic purposes, including the development of novel treatments for genetic disorders and cancers. The versatility of gRNA allows scientists and researchers to precisely target and modify specific genes, opening up possibilities for personalized medicine. The gRNA market is characterized by ongoing research and development activities aimed at refining and expanding the capabilities of CRISPR technology. The race to develop more efficient and precise genome editing tools has spurred collaborations between biotechnology companies, academic institutions, and research organizations. As a result, the gRNA market is expected to witness continuous growth in the coming years. However, ethical and regulatory challenges associated with genome editing technologies, including concerns about off-target effects and unintended consequences, pose potential obstacles to the market's expansion. Striking a balance between technological advancement and ethical considerations will be crucial for the sustained growth of the gRNA market. Despite challenges, the potential applications and transformative impact of gRNA technology make it a focal point in the rapidly evolving landscape of genetic engineering.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 498.23 Million
Market Size 2029USD 1370.40 Million
CAGR 2024-202918. 54%
Fastest Growing SegmentPharmaceutical & Biotechnology Companies
Largest MarketNorth America

Key Market Drivers

Advancements in Genetic Engineering

Advancements in genetic engineering have been instrumental in shaping the landscape of the global gRNA (guide RNA) market. The relentless pursuit of precision and efficiency in genome editing technologies, particularly CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), has led to groundbreaking developments with far-reaching implications. Scientists and researchers have made significant strides in refining the mechanisms of gRNA, allowing for more accurate targeting and modification of specific genes. These advancements have not only expanded the scope of genetic engineering applications but have also fueled the commercialization of gRNA technologies across diverse sectors. One notable breakthrough is the continuous improvement in CRISPR-Cas systems, with an emphasis on reducing off-target effects and enhancing on-target precision. This progress has bolstered confidence in the safety and efficacy of genome editing tools, driving increased adoption across industries. The development of high-throughput screening techniques and innovative delivery methods for gRNA has further streamlined the gene-editing process, making it more accessible and applicable in various research and commercial settings. The global gRNA market has been positively influenced by these advancements, attracting substantial investments and partnerships between biotechnology firms and research institutions. The synergistic collaboration between technology developers and end-users has facilitated the integration of cutting-edge genetic engineering tools, fostering a robust market environment. As genetic engineering continues to evolve, the gRNA market stands at the forefront, poised to leverage ongoing advancements for applications ranging from agriculture to personalized medicine.

Increased Research and Development Activities

The global gRNA (guide RNA) market is experiencing significant expansion, propelled by a surge in research and development activities aimed at advancing genome editing technologies. Research initiatives focused on enhancing the precision, efficiency, and safety of gRNA, particularly in the context of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), have become a cornerstone of innovation in the field. Scientists and biotechnologists are actively engaged in understanding the intricacies of gRNA design, delivery methods, and the overall CRISPR system, leading to breakthroughs that address existing challenges and broaden the range of applications. Increased R&D efforts have resulted in the development of novel gRNA variants, with improved specificity and reduced off-target effects, fostering greater confidence in the reliability of genome editing tools. Continuous exploration of alternative CRISPR systems and bioinformatics tools has expanded the toolkit available to researchers, enabling them to navigate the complexities of gene editing with greater precision. The efforts to optimize the delivery of gRNA into target cells have contributed to the development of more efficient and scalable methods, making genome editing more accessible across various industries. The collaborative nature of these research endeavors, involving academia, industry, and research institutions, has accelerated the pace of discovery in the gRNA field. This heightened research activity not only fuels the evolution of genetic engineering technologies but also attracts substantial investments, driving the commercialization of advanced gRNA applications. The global gRNA market is thus intricately linked to the dynamic landscape of research and development, with ongoing efforts shaping its trajectory and ensuring its continued growth and relevance in diverse sectors.

Rising Demand for Personalized Medicine

The global gRNA (guide RNA) market is witnessing a compelling surge in demand, driven in no small part by the rising prominence of personalized medicine. As the understanding of the human genome advances, there is an increasing recognition of the potential of gRNA technology, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework, to revolutionize healthcare. Personalized medicine aims to tailor medical treatments to individual genetic profiles, and gRNA plays a pivotal role in this paradigm shift. The ability of gRNA to precisely target and modify specific genes opens avenues for developing customized therapies for a spectrum of genetic disorders, ranging from rare diseases to more prevalent conditions. This demand is underscored by the quest to find targeted and effective treatments with minimal side effects, aligning with the ethos of precision medicine. The pharmaceutical industry is increasingly investing in research and development initiatives centered on gRNA applications, striving to unlock the full therapeutic potential of genome editing. The advent of CRISPR-based gene therapies for various genetic disorders has heightened interest in the gRNA market, creating a symbiotic relationship between the demand for personalized medicine and the technological capabilities of gRNA. The gRNA market, as an integral component of the personalized medicine landscape, is poised for substantial growth. The convergence of cutting-edge genetic engineering technologies with the paradigm shift towards individualized healthcare is reshaping the global healthcare landscape and positioning gRNA as a cornerstone in the quest for more effective and tailored medical interventions.

Key Market Challenges

Off-Target Effects

Off-target effects represent a significant challenge in the global gRNA (guide RNA) market, posing concerns about the precision and safety of genome editing technologies. Off-target effects occur when the CRISPR system, guided by gRNA, inadvertently modifies unintended genomic locations, leading to potentially unpredictable consequences. This phenomenon is a critical consideration in therapeutic applications, as unintended alterations to the genome could result in adverse effects or unintended mutations. Researchers are actively engaged in developing strategies to minimize off-target effects, employing advanced bioinformatics tools, improved gRNA design algorithms, and enhanced CRISPR enzyme engineering. Despite ongoing efforts, achieving complete elimination of off-target effects remains a complex task. The unique characteristics of individual genomes, variations in target sequences, and the complexity of genomic interactions contribute to the challenge. As the demand for precision genome editing increases, the gRNA market is driven by innovations aimed at refining and optimizing CRISPR technologies to mitigate the risks associated with off-target effects. Addressing off-target effects is not only crucial for therapeutic applications but also essential in other sectors such as agriculture and research. Striking a balance between efficiency and precision is paramount to harness the full potential of gRNA technology without compromising safety. The market's response to this challenge involves continuous research, technological advancements, and a collaborative effort among scientists, industry stakeholders, and regulatory bodies to establish guidelines that ensure responsible and reliable use of gRNA-based genome editing tools. The resolution of off-target effects is pivotal in fostering confidence in the gRNA market and unlocking its diverse applications across various fields.

Delivery Methods

Efficient delivery methods constitute a critical aspect of the global gRNA (guide RNA) market, playing a pivotal role in determining the success of genome editing applications, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework. The challenge lies in delivering gRNA into target cells with precision, avoiding off-target effects and ensuring the effective incorporation of genetic modifications. Various delivery methods are under constant exploration and development to optimize the efficiency, safety, and scalability of gRNA technology. Viral vectors, such as lentiviruses and adeno-associated viruses (AAVs), have been widely employed for delivering gRNA into cells due to their ability to efficiently integrate genetic material. However, concerns about immunogenicity, limited cargo capacity, and potential side effects necessitate ongoing research into alternative delivery platforms. Non-viral methods, including lipid nanoparticles, electroporation, and physical methods like microinjection, are being investigated for their potential to provide safer and more cost-effective delivery solutions. The choice of delivery method is influenced by the specific application and target cells, emphasizing the need for versatility in the gRNA market. Innovations in nanotechnology and biomaterials contribute to the development of delivery systems that enhance cell specificity, reduce toxicity, and improve the overall efficacy of gRNA delivery. Overcoming delivery challenges is crucial for expanding the reach of gRNA technologies, ensuring their applicability in diverse industries such as therapeutics, agriculture, and research. As the global gRNA market continues to evolve, advancements in delivery methods will play a pivotal role in shaping the accessibility and effectiveness of genome editing tools across various sectors.

Key Market Trends

Therapeutic Applications

The global gRNA (guide RNA) market is witnessing a notable trend with the increasing prominence of therapeutic applications, marking a transformative era in medicine. The rise of gRNA technology, particularly within the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) framework, has opened unprecedented opportunities for the development of targeted and personalized therapies. Researchers and pharmaceutical companies are actively exploring the therapeutic potential of gRNA in treating genetic disorders, rare diseases, and certain types of cancers. Clinical trials and research endeavors are underway to harness the precision of gRNA for gene editing in somatic cells, offering the prospect of novel and more effective treatment modalities. The ability of gRNA to precisely target and modify specific genes holds promise for addressing the root causes of genetic diseases at the molecular level. This trend aligns with the broader movement towards precision medicine, where treatments are tailored to individual genetic profiles. As the therapeutic landscape continues to evolve, the gRNA market is positioned as a key player in ushering in a new era of customized medical interventions. Challenges such as off-target effects and ethical considerations remain, but the growing interest and investment in therapeutic applications underscore the potential of gRNA to revolutionize healthcare and contribute significantly to the advancement of precision medicine. The upward trajectory of therapeutic applications is expected to be a driving force in the continued growth and diversification of the global gRNA market.

Focus on CRISPR-Cas Systems

The global gRNA (guide RNA) market is experiencing a distinct trend marked by a heightened focus on CRISPR-Cas systems. As the cornerstone of precise genome editing, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology relies on guide RNA to direct Cas proteins to specific genomic locations, enabling targeted modifications. The continuous refinement and optimization of CRISPR-Cas systems have become a focal point of research and development within the gRNA market. Scientists and biotechnologists are actively engaged in exploring novel Cas proteins, engineering existing ones for enhanced specificity, and developing alternative CRISPR systems beyond the well-known Cas9. This trend is driven by the quest for greater precision and reduced off-target effects in genome editing applications. The versatility of CRISPR-Cas systems allows researchers to tailor their approach to different genetic contexts and overcome challenges associated with specific gene-editing scenarios. The rise in interest extends beyond academic research, with biotechnology companies investing significantly in the development of CRISPR-based tools for applications in therapeutics, agriculture, and various research fields. As CRISPR-Cas systems become more sophisticated and adaptable, the gRNA market is poised to benefit from the expanding toolkit of genome editing technologies. The focus on CRISPR-Cas systems aligns with the market's pursuit of refining and advancing gRNA technology, making it an integral component in the continuous evolution of genetic engineering and its diverse applications across industries.

Segmental Insights

Product & Services Insights

Based on Product & Services, product segment dominated the Global gRNA Market in 2023. This is ascribed due to the pivotal role of gRNA as a key component in CRISPR-based gene editing systems. Researchers and biotechnology companies widely utilize gRNA products to design and customize CRISPR experiments for targeted gene modifications. The demand for high-quality, reliable gRNA products for precise and efficient gene editing drives the dominance of this segment. As CRISPR technology becomes increasingly essential in various fields, including medicine and agriculture, the popularity and reliance on gRNA products for genetic manipulation contribute significantly to their dominance in the global market.

End Use Insights

Based on end use, pharmaceutical and biotechnology companies segment dominated the Global gRNA Market in 2023. This is ascribed due to its pivotal role in driving research, development, and commercialization of gene-editing technologies. These companies possess the expertise, infrastructure, and financial resources required for innovative gRNA (guide RNA) applications like CRISPR-Cas9. With a focus on therapeutic advancements, these firms lead in translating gene-editing discoveries into viable treatments for genetic disorders, cancers, and other diseases. The dominance of this segment underscores the critical involvement of pharmaceutical and biotechnology companies in advancing gRNA technologies from laboratories to clinical applications, shaping the market landscape with cutting-edge genetic therapies.

Regional Insights

North America dominate the global gRNA market in 2023. The region's dominance is notably influenced by the significant presence of key industry players in the region. This local concentration of major players contributes to the overall growth of the gRNA industry in North America. The region experiences a surge in research and development investments by these key players, aimed at fostering the creation of innovative and advanced gRNA products. The collaborative efforts of industry leaders and increased R&D spending collectively propel North America to the forefront of the global gRNA market.

Key Market Players

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

System Biosciences, LLC

Jena Bioscience GmbH

Merck KGaA

Azenta US, Inc.

Takara Bio, Inc.

Synbio Technologies

Revvity, Inc.

Synthego Corporation

Report Scope:

In this report, the Global gRNA Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

gRNA Market, By Type:

    Research-Use GMP-grade

gRNA Market, By Product & Services:

    Products

gRNA Final Products

gRNA Synthesis Products

gRNA Synthesis Kits

Plasmids

Others

    Custom gRNA Synthesis Services

gRNA Market, By Application:

    Genome Engineering Disease Model Studies Functional Genomics Epigenetics Others

gRNA Market, By End Use:

    Pharmaceutical & Biotechnology Companies Academic Research Institutes CMOs & CROs

gRNA Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global gRNA Market.

Available Customizations:

Global gRNA Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Voice of Customer

4. Executive Summary

  • 4.1. Overview of the Market
  • 4.2. Overview of Key Market Segmentations
  • 4.3. Overview of Key Market Players
  • 4.4. Overview of Key Regions/Countries
  • 4.5. Overview of Market Drivers, Challenges, Trends

5. Global gRNA Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Research-Use, GMP-grade)
    • 5.2.2. By Product & Services (Products (gRNA Final Products, gRNA Synthesis Products, gRNA Synthesis Kits, Plasmids, Others)), Custom gRNA Synthesis Services)
    • 5.2.3. By Application (Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others)
    • 5.2.4. By End-Use (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, CMOs & CROs)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Product & Services
    • 5.3.3. By Application
    • 5.3.4. By End-Use
    • 5.3.5. By Region

6. Asia Pacific gRNA Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product & Services
    • 6.2.3. By Application
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China gRNA Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product & Services
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use
    • 6.3.2. India gRNA Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product & Services
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Australia gRNA Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product & Services
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use
    • 6.3.4. Japan gRNA Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Product & Services
        • 6.3.4.2.3. By Application
        • 6.3.4.2.4. By End-Use
    • 6.3.5. South Korea gRNA Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Product & Services
        • 6.3.5.2.3. By Application
        • 6.3.5.2.4. By End-Use

7. Europe gRNA Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product & Services
    • 7.2.3. By Application
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France gRNA Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product & Services
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use
    • 7.3.2. Germany gRNA Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product & Services
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use
    • 7.3.3. Spain gRNA Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product & Services
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy gRNA Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product & Services
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use
    • 7.3.5. United Kingdom gRNA Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product & Services
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use

8. North America gRNA Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product & Services
    • 8.2.3. By Application
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States gRNA Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product & Services
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use
    • 8.3.2. Mexico gRNA Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product & Services
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Canada gRNA Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product & Services
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use

9. South America gRNA Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product & Services
    • 9.2.3. By Application
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil gRNA Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product & Services
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use
    • 9.3.2. Argentina gRNA Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product & Services
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use
    • 9.3.3. Colombia gRNA Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product & Services
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use

10. Middle East and Africa gRNA Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product & Services
    • 10.2.3. By Application
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa gRNA Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product & Services
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Saudi Arabia gRNA Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product & Services
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use
    • 10.3.3. UAE gRNA Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product & Services
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use
    • 10.3.4. Egypt gRNA Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Product & Services
        • 10.3.4.2.3. By Application
        • 10.3.4.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches (If Any)
  • 12.3. Mergers & Acquisitions (If Any)

13. Global gRNA Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (In case of listed)
    • 15.1.5. Recent Developments
    • 15.1.6. SWOT Analysis
  • 15.2. Agilent Technologies, Inc.
  • 15.3. System Biosciences, LLC
  • 15.4. Jena Bioscience GmbH
  • 15.5. Merck KGaA
  • 15.6. Azenta Us, Inc.
  • 15.7. Takara Bio, Inc.
  • 15.8. Synbio Technologies
  • 15.9. Revvity, Inc.
  • 15.10.Synthego Corporation

16. Strategic Recommendations

17. About Us & Disclaimer